ATHA: Athira Pharma Total Debt to Capital

Athira Pharma, Inc. (ATHA) is developing neuron regeneration therapies for Alzheimer's disease, targeting the neurodegeneration segment. The company is currently utilizing its accumulated reserves to fund costly research and development, a trend reflected in the price action with the 0.03 indicator. Simultaneously, the business is implementing ESG principles, minimizing its carbon footprint and transitioning to closed-loop water systems at its chemical production facilities to protect the environment.

The stability of Athira Pharma, Inc. (ATHA) depends on its ability to fund neurotherapy development without excessive borrowing. The financial leverage ratio (total debt-to-equity) at 0.03 measures the proportion of borrowed resources relative to equity, where low values minimize bankruptcy risks in the event of delayed drug commercialization, while high values signal a critical debt load that reduces the fair value of the shares.